cdc7-in-1

Cdc7-IN-1 is a highly selective and ATP competitive inhibitor of Cdc7 kinase (IC50: 0.6 nM at 1 mM ATP). It potently inhibits Cdc7 activity in cancer cells and effectively induces cell death.

Cdc7-IN-15 (Example 108) is a cdc7 kinase inhibitor with potential applications in cancer research [1].

Cdc7-IN-17 is a potent inhibitor of CDC7 with an IC50 of <10 μM, applicable in cancer research [1].

Cdc7-IN-12 (compound 1) is a potent CDC7 inhibitor (IC50 < 1 nM) with potential applications in cancer research, demonstrating antiproliferative activity in COLO205 cells with an IC50 of 100-1000 nM [1].

Cdc7-IN-19 (compound 1-1) is a potent CDC7 inhibitor with an IC50 of 1.49 nM [1].

Cdc7-IN-13 (compound 84) is a highly potent CDC7 inhibitor with an IC50 value of less than 1 nM, showing significant potential for cancer research [1].

Cdc7-IN-14 (compound 82) is a highly potent CDC7 inhibitor with an IC50 value of less than 1 nM, exhibiting promising potential for cancer research [1].

(S)-Cdc7-IN-18, a potent CDC7 inhibitor, effectively impedes the overactivation of MCM2, a crucial tumor cell marker, induced by huCdc7 overexpression. Consequently, it inhibits the aberrant proliferation of tumor cells. This compound, exhibits promise for cancer disease research [1].

Cdc7-IN-18 (compound 1-2) is a highly effective inhibitor of the CDC7 enzyme, with an IC50 value of 1.29 nM for the Cdc7/DBF4 enzyme. Additionally, this compound exhibits strong antiproliferative activities, with an IC50 value of 53.62 nM in COLO205 cells [1].

Cdc7-IN-10 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in studies of proliferative diseases.

Cdc7-IN-11 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in the study of proliferative diseases.

LY3143921 ((S)-Example 2) is an orally active inhibitor of CDC7 kinase with broad in vitro anticancer activity [1].

Cdc7-IN-9 can be used for the research of cancer which is a potent inhibitor of Cdc7 [1].

Cdc7-IN-8, a potent inhibitor, targets Cdc7, a serine/threonine kinase responsible for activating MCM promotion through phosphorylation of the microchromosome maintenance protein (MCM protein). MCM protein, an essential component of DNA replication initiation, plays a crucial role. Cdc7-IN-8 holds promise in cancer disease research (WO2021032170A1, compound 1-1/1-2) [1].

LY3143921 ((S)-Example 2) hydrate is an orally active CDC7 kinase inhibitor with broad in vitro anticancer activity [1].